Spero Therapeutics, Inc. (SPRO) Return on equity 2017–2025
Spero Therapeutics, Inc. (SPRO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
14.5%FY2025 · since FY2017: -45.8% → 14.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 14.5% | +163.2 pp |
| FY2024 | -148.7% | -170.0 pp |
| FY2023 | 21.3% | +82.5 pp |
| FY2022 | -61.1% | +40.6 pp |
| FY2021 | -101.7% | -42.4 pp |
| FY2020 | -59.3% | +22.4 pp |
| FY2019 | -81.7% | -45.6 pp |
| FY2018 | -36.1% | +9.7 pp |
| FY2017 | -45.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRO financial trends
SPRO RevenueSPRO Net incomeSPRO Net marginSPRO Gross profitSPRO Gross marginSPRO Operating incomeSPRO Operating marginSPRO Operating cash flowSPRO Free cash flowSPRO Capital expendituresSPRO Stock buybacksSPRO Dividends paidSPRO Total assetsSPRO Total liabilitiesSPRO Shareholders’ equitySPRO overview →